Please assess the completion status of the following clinical trial:

Trial Title: A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Rapid diagnostic test, PCR, or viral culture positive for influenza in the 96 hours prior to first dose~* Immunocompromised participants with primary or secondary immunodeficiency~* Symptoms suggestive of influenza-like illness~* Use of an effective contraceptive, as specified by protocol; women of childbearing potential cannot be pregnant or breastfeeding~Exclusion Criteria:~* Influenza vaccination with live attenuated vaccine in the 2 weeks prior to randomization~* Antiviral treatment for influenza in 2 weeks prior to randomization~* Severe hepatic impairment~* Any current renal replacement therapy~* Any gastrointestinal disorders which may interfere with the absorption of oseltamivir~* Participation in a study with an investigational drug from 4 weeks prior to study start until study end

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional dose (Type: EXPERIMENTAL): Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.
- Double dose (Type: EXPERIMENTAL): Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).